Pfizer told by FDA that Facebook ads for Adcetris ‘false or misleading’

In a letter to Pfizer (PFE) posted to the site of the FDA, the agency stated: “The Office of Prescription Drug Promotion of the U.S. Food and Drug Administration has reviewed the promotional communications, social media posts, ‘Adcetris PTCL Facebook Ads Set’ for Adcetris for injection, for intravenous use submitted by Pfizer, under cover of Form FDA 2253. FDA has determined that the Facebook ads are false or misleading. Thus, the Facebook ads misbrand Adcetris and make the distribution of the drug in violation of the Federal Food, Drug, and Cosmetic Act.”